Multimodal Pain Management of Femoral Neck Fractures Treated With Hemiarthroplasty


The purpose of this study was to evaluate a multimodal pain management program incorporating periarticular injections of liposomal bupivacaine after hemiarthroplasty treatment of femoral neck fractures. This retrospective study selected patients treated with periarticular injections of liposomal bupivacaine within the multimodal pain management program (LBUP) (n = 100) and a control group of patients treated without local infiltration (n = 78). Similar pain control was achieved between both groups from day 1 to day 4 postsurgery (min p = .392). Length of stay was significantly lower for LBUP patients (4.8 days vs. 5.7 days, p = .013), and LBUP patients were significantly more likely to be ambulatory at discharge (82% vs. 69%, p = .013). LBUP patients were also less likely to need the intensive care unit (4% vs. 14%, p = .027). The percentage of patients with at least one opioid-related adverse event was lower in the LBUP group (3% vs. 8%, p = .156) as was the 90-day mortality rate (2% vs. 8%, p = .069), but the differences were not statistically significant. (Journal of Surgical Orthopaedic Advances 28(1):58–62, 2019)
Key words: hemiarthroplasty, hip fracture, liposomal bupivacaine, multimodal pain management

Hank L. Hutchinson, MD; David J. Jaekel, PhD; Scott T. Lovald, PhD; Heather N. Watson, PhD; and Kevin L. Ong, PhD, PE